ImmunityBio, Inc.
No trades
No trades
Price target
12.750.000.00%
The 4 analysts offering 1-year price forecasts have a max estimate of — and a min estimate of —.
Analyst rating
Based on 4 analysts giving stock ratings in the past 3 months.
EPS
Reported
Estimate
Metrics
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Metrics
Reported
Estimate
Surprise
This is not investment advice and doesn't take into account your personal circumstances. It isn't a recommendation to buy, sell, or hold any asset. See the Terms of Use and always do your own research.
Frequently asked questions
The current price of IBRX is 7.60 USD — it has increased by 1.80% in the past 24 hours. Watch ImmunityBio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ImmunityBio, Inc. stocks are traded under the ticker IBRX.
IBRX stock has risen by 12.80% compared to the previous week, the month change is a −14.52% fall, over the last year ImmunityBio, Inc. has showed a 206.45% increase.
We've gathered analysts' opinions on ImmunityBio, Inc. future price: according to them, IBRX price has a max estimate of 15.00 USD and a min estimate of 12.00 USD. Watch IBRX chart and read a more detailed ImmunityBio, Inc. stock forecast: see what analysts think of ImmunityBio, Inc. and suggest that you do with its stocks.
IBRX reached its all-time high on Feb 22, 2021 with the price of 45.42 USD, and its all-time low was 0.93 USD and was reached on Dec 26, 2018. View more price dynamics on IBRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IBRX stock is 2.41% volatile and has beta coefficient of 1.35. Track ImmunityBio, Inc. stock price on the chart and check out the list of the most volatile stocks — is ImmunityBio, Inc. there?
Today ImmunityBio, Inc. has the market capitalization of 8.05 B, it has decreased by −7.19% over the last week.
Yes, you can track ImmunityBio, Inc. financials in yearly and quarterly reports right on TradingView.
ImmunityBio, Inc. is going to release the next earnings report on Nov 5, 2026. Keep track of upcoming events with our Earnings Calendar.
IBRX earnings for the last quarter are −0.22 USD per share, whereas the estimation was −0.08 USD resulting in a −175.00% surprise. The estimated earnings for the next quarter are −0.07 USD per share. See more details about ImmunityBio, Inc. earnings.
ImmunityBio, Inc. revenue for the last quarter amounts to 51.24 M USD, despite the estimated figure of 49.70 M USD. In the next quarter, revenue is expected to reach 59.23 M USD.
IBRX net income for the last quarter is −230.38 M USD, while the quarter before that showed −632.78 M USD of net income which accounts for 0.00% change. Track more ImmunityBio, Inc. financial stats to get the full picture.
No, IBRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 12, 2026, the company has 691 employees. See our rating of the largest employees — is ImmunityBio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ImmunityBio, Inc. EBITDA is −235.20 M USD, and current EBITDA margin is −212.29%. See more stats in ImmunityBio, Inc. financial statements.
Like other stocks, IBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ImmunityBio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ImmunityBio, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ImmunityBio, Inc. stock shows the strong buy signal. See more of ImmunityBio, Inc. technicals for a more comprehensive analysis.